Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2015-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp Introduces a Test to Identify Enterovirus D-68 (EV-D68)

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 18, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a reflex test to identify enterovirus D68 (EV-D68), which is associated with severe respiratory illness that primarily affects children.

LabCorp Named Laboratory Service Provider of the Pro Football Legends

MOUNT LAUREL, N.J. & BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 17, 2014-- Pro Football Legends, the commercial marketing arm of the National Football League Alumni, Inc. (NFL Alumni) and Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) are pleased to announce that they have

Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 16, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) and Covance Inc. ( Covance ) (NYSE: CVD) jointly announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act,

LabCorp Announces Acquisition of Bode Technology

Acquisition expands LabCorp’s forensic DNA testing and relationship analysis capabilities BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 5, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of Bode Technology Group, Inc.

LabCorp Completes Acquisition of LIPOSCIENCE

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 21, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ:LPDX), effective November 20, 2014 . At a special meeting held on November 20, 2014 , LIPOSCIENCE’s

LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare Diagnostics Company

Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commercialization Transaction expected to be

Laboratory Corporation of America® Holdings Announces 2014 Third Quarter Results and Increases 2014 EPS Guidance

Strong volume growth drives sales of $1.55 billion Diluted EPS of $1.59 ; Adjusted EPS of $1.80 Operating Cash Flow of $176 million ; Free Cash Flow of $123 million 2014 Adjusted EPS guidance raised to $6.70 - $6.80 BURLINGTON, N.C. --(BUSINESS WIRE)--Oct.

LabCorp Introduces HIV-1 Next Generation Sequencing Assay to Support Drug Regimen Changes in HIV Suppressed Patients

GenoSure Archive SM is the first genotypic drug resistance assay to interrogate HIV-1 DNA BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 20, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) and Monogram Biosciences, Inc. , part of the LabCorp Specialty Testing Group , today

LabCorp’s Acquisition of LipoScience Clears Antitrust Approval

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 15, 2014-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to